Costs & health insurance
Cost approval for cannabis: the application step by step
Your doctor applies to the health insurer for cost approval for cannabis medicines. What the law requires, who decides and which deadlines apply.
Key points
- Cannabis medicines are not in the benefits catalogue of basic health insurance. Coverage is only possible in the individual case under Art. 71a ff. KVV and always requires a cost approval.
- The application is made by your doctor. The health insurer decides after first consulting its medical adviser.
- If the application is complete, the insurer must decide within two weeks. If it refuses, it must give reasons for the decision.
- Do you disagree with a refusal? You can request a written ruling and lodge an objection within 30 days.
- According to the FOPH, a great therapeutic benefit is not to be expected even with ready-made medicines. Approval is therefore not guaranteed.
Cost approval for cannabis medicines is not applied for by the patient, but by the treating doctor with the health insurer. The insurer decides after first consulting its medical adviser. If the application is complete, it must do so within two weeks.1
Approval is not guaranteed. Cannabis medicines are not in the benefits catalogue of basic health insurance, and coverage in the individual case is subject to strict requirements. The Federal Office of Public Health (FOPH) states that a great therapeutic benefit is not to be expected even with ready-made medicines.2
Why cannabis needs a cost approval
Basic health insurance pays for medicines on the list of pharmaceutical specialities. Magistral preparations from the pharmacy are covered if their ingredients are listed in the list of medicines with tariff.6 All benefits must also be effective, appropriate and cost-effective, and efficacy must be demonstrated by scientific methods.4
According to the FOPH, the benefits catalogue currently contains no cannabis medicines. The criteria of efficacy, appropriateness and cost-effectiveness have so far not been found to be met for inclusion. Coverage is therefore at most possible as so-called individual case coverage under Art. 71a ff. of the Health Insurance Ordinance (KVV), and this always requires a cost approval.2 The 2022 change in the law did not change these requirements.3
Requirements under Art. 71a KVV
Art. 71a para. 1 KVV names three situations in which basic health insurance covers a medicine by way of exception. For cannabis medicines, the FOPH names two of them.1,2
- Prerequisite for another benefit: The use of the medicine is indispensable for carrying out another benefit covered by basic health insurance, and that benefit is clearly the main focus.
- Great therapeutic benefit without alternative: The medicine is expected to have a great therapeutic benefit against a disease that can be fatal or lead to severe and chronic health impairment. At the same time, because there are no therapeutic alternatives, no other effective and authorised treatment method is available.
The third situation in the law concerns post-exposure prophylaxis and plays no role for cannabis.1 Art. 71b and 71c KVV apply the same requirements to authorised medicines that are not on the list of pharmaceutical specialities and to imported medicines not authorised in Switzerland.1
Cost approval step by step
The procedure follows from Art. 71d KVV and the Federal Health Insurance Act (KVG). Details such as forms are regulated by the health insurers themselves.1,4
- Medical assessment: Your doctor clarifies whether a cannabis medicine is a medical option and whether the requirements of Art. 71a KVV could be met.
- Application to the health insurer: The doctor submits the application for cost approval to your insurer. The insurer only covers the costs on this special approval.
- Review by the medical adviser: The insurer consults its medical adviser, who reviews the requirements for the obligation to pay and is independent in their judgement.
- Decision: If the application is complete, the insurer decides within two weeks.
- Billing: If approved, the provider invoices the insurer for the actual costs.
What the doctor submits
The KVV does not prescribe a specific form. However, the application must show that the legal requirements are met.1 In practice, this typically includes:
- the diagnosis and how severe and chronic the impairment is,
- which treatments have been tried so far and why they were not sufficient or not tolerated,
- the intended medicine and the expected effect, based on the available evidence.
The medical adviser can request the necessary information from the doctor. Providers must supply it.4 The more complete the application, the sooner the two-week deadline can start running.
The role of the medical adviser
Medical advisers are appointed by the health insurers or their associations after consulting the cantonal medical societies. They must have worked for at least five years in a medical practice or in a senior hospital position.4
They advise the insurer on specialist medical questions and on questions of coverage. Neither the insurer nor the providers can give them instructions. If information cannot be obtained otherwise, they can also examine insured persons personally.4 For you, this means: medical documents go to the medical adviser service, not to the insurer’s administrative staff.
What you can do yourself
The application is made by the doctor. You can still support the process.
- Have documents ready: Reports from previous treatments, hospital reports and a list of your medicines help make the application complete.
- Inform the insurer: Ask your insurer whether it uses its own form and where it should be sent.
- Wait for the decision: The insurer only pays on special approval.1 If you start treatment before the decision, you bear the risk of paying the costs yourself.
- Request the decision in writing: In the event of a refusal, written reasons help with the next step.
Deadlines and amount of coverage
The only deadline for the decision named in the law is two weeks from the complete application. How long an approval is valid is not specified in the KVV. Ask your insurer whether and when it requires a renewal.1
The amount of coverage is determined by the insurer in agreement with the marketing authorisation holder. For cases with great therapeutic benefit, the KVV provides for a price reduction of at most 50 per cent so that the costs are in reasonable proportion to the benefit.1 Even with approval, the deductible and co-payment of basic health insurance also apply.4
2 weeks
If the health insurer refuses cost approval
If the insurer refuses, it must give reasons for the decision to your doctor and to you. If the refusal is based on the assessment of the therapeutic benefit, this must be enclosed.1
If you disagree with the decision, you can request a written ruling. The insurer must issue a written ruling on benefits that the person concerned does not agree with. The ruling contains information on legal remedies and must give reasons if it does not fully grant your request. You can lodge an objection against a ruling with the insurer within 30 days. The objection procedure is free of charge.5 Whether such a step is worthwhile, or whether a new application with further documents makes more sense, is something to discuss with your doctor.
Independently of this, according to the FOPH, supplementary insurance may be liable to pay if it has corresponding cover. Your insurer can tell you what your policy covers.2
How it works at evidena
At evidena, the doctor decides after an assessment whether a cannabis medicine is an option. There is no entitlement to a prescription. If a prescription is issued, it must be filled at a pharmacy within one month. As a rule, it covers the need for one month, in justified cases up to three months. You can book an appointment at portal.evidena.care. We answer questions about costs and cost approval via WhatsApp or at info@evidena.care. You can see what the consultation and medicines cost on the page Costs. Terms such as list of pharmaceutical specialities or medical adviser are explained in the glossary.
Conclusion
Cost approval is applied for by your doctor; the insurer decides after consulting the medical adviser within two weeks of the complete application. The legal hurdles are high, and approval is not guaranteed. In the event of a refusal, a ruling and an objection remain open to you. The section Costs and health insurance gives an overview of all cost questions.
Frequently asked questions
Who applies for cost approval?
The treating doctor. The doctor explains to the health insurer why the legal requirements should be met in your case.
How long does the decision take?
If the application is complete, the insurer decides within two weeks under Art. 71d KVV. If documents are missing, this deadline only begins once the application is complete.
Who decides on cost approval?
The health insurer, after first consulting its medical adviser. Medical advisers are independent in their judgement.
Am I entitled to cost approval?
No. Basic health insurance only covers cannabis medicines by way of exception if the requirements of Art. 71a KVV are met. The insurer checks this in the individual case.
What can I do if the insurer refuses?
You can request a written ruling with reasons and lodge an objection within 30 days. The objection procedure is free of charge.
Sources
- Verordnung über die Krankenversicherung (KVV), SR 832.102, Art. 71a bis 71d, Fassung vom 1. August 2026, Fedlex (accessed 13 November 2026)
- FAQ Cannabisarzneimittel, Rubrik «Werden die Behandlungskosten von den Krankenkassen vergütet?», Bundesamt für Gesundheit BAG (accessed 13 November 2026)
- Gesetzesänderung Cannabisarzneimittel, Bundesamt für Gesundheit BAG (accessed 13 November 2026)
- Bundesgesetz über die Krankenversicherung (KVG), SR 832.10, Art. 32, 57 und 64, Fassung vom 1. Juli 2026, Fedlex (accessed 13 November 2026)
- Bundesgesetz über den Allgemeinen Teil des Sozialversicherungsrechts (ATSG), SR 830.1, Art. 49, 51 und 52, Fedlex (accessed 13 November 2026)
- Ratgeber «Die obligatorische Krankenversicherung», Bundesamt für Gesundheit BAG, Stand 1. Januar 2026 (accessed 13 November 2026)